British pharmaceutical company, GlaxoSmithKline and its distributor in Syria have been accused of paying bribes to secure business, Reuters has reported, citing a whistleblower’s email. The allegations relate to its former consumer healthcare operations in Syria, which were closed down in 2012 due to the worsening civil war in the country. GSK said it was investigating the latest claims dating back to 2010, which were laid out in the email received by the company on July 18. “We have zero tolerance for any kind of unethical behaviour. We will thoroughly investigate all the claims made in this email,” GSK said.